改性柑橘果胶的制备、表征及抗癌活性

高等学校化学学报 ›› 2010, Vol. 31 ›› Issue (5): 964.

改性柑橘果胶的制备、表征及抗癌活性

张文博¹, 刘长忠², 高林¹

1. 天津大学药物科学与技术学院, 天津 300072;
2. 河南科技学院动物科学学院, 新乡 453003

收稿日期:2009-07-02 出版日期:2010-05-10 发布日期:2010-05-10
通讯作者: 张文博, 男, 博士, 主要从事生化药物研究. E-mail: zhwenbo@gmail.com

Modified Citrus Pectin: Preparation, Characterization and Anti-cancer Activities

ZHANG Wen-Bo^1*, LIU Chang-Zhong², GAO Lin¹

1. School of Pharmaceutical and Technology, Tianjin University, Tianjin 300072, China;
2. School of Animal Sciences, Henan Institute of Science and Technology, Xinxiang 453003, China

Received:2009-07-02 Online:2010-05-10 Published:2010-05-10
Contact: ZHANG Wen-Bo. E-mail: zhwenbo@gmail.com

摘要/Abstract

摘要：

采用琼脂糖凝胶电泳、比旋度测试、HPSEC-RID、IR、¹H NMR、¹³C NMR、高碘酸氧化及甲基化分析等手段对改性柑橘果胶(MCP)进行了分析, 结果表明, MCP是一种均一性多糖, 分子量约为21000~66000, 糖醛酸质量分数为81.0%, 酯化度为2.13%. MCP的中性单糖残基主要包括鼠李糖(Rha)、阿拉伯糖(Ara)、木糖(Xyl)和半乳糖(Gal)等, 其摩尔比约为1.0∶1.5∶1.4∶1.3, 主链包括HG和RG, 分支结构含有末端Gal, Xyl和Ara. 选用3种小鼠移植性肿瘤模型对MCP的抗肿瘤生长活性进行研究. 结果表明, MCP对肝癌H22细胞有较强抑制作用, 高剂量下抑制率可达47.8%; 对宫颈癌U14细胞的抑制率在高剂量及中等剂量下分别达到36.5%和38.5%; 对肉瘤S180没有抑制活性. MCP的抗肝癌和抗宫颈癌活性为首次发现.

关键词: 改性柑橘果胶; 多糖; 抗癌活性

Abstract:

Agarose gel electrophoresis, specific rotatory, HPSEC-RID, IR, ¹H NMR, ¹³C NMR, periodate oxidation, GC-MS and methylation analysis were applied to investigate the homogeneity, chemical properties and structural features of modified citrus pectin(MCP). Results demonstrated that MCP was a homogeneous polysaccharide. Its molecular weight ranged from 21000 to 66000; the content of galacturonic acid was 81.0% and the degree of esterification was 2.13%. MCP contains Gal, Xyl, Rha and Ara; their molar ratio was 1.0∶1.5∶1.4∶1.3. Methylation analysis results confirmed that MCP had neutral sugar residues composed of Xyl, Ara and terminal Gal. Heptoma H22 was significantly inhibited by MCP and the inhibitor rate was 47.8%(n=10, p<0.01) at high-dose level(4 mg/kg). MCP also demonstrated anti-cervical carcinoma activity in U14 mice model. No anti-cancer activity was observed in Sarcoma 180 group.

Key words: Modified citrus pectin; Polysaccharide; Anti-cancer activity

TrendMD:

张文博, 刘长忠, 高林. 改性柑橘果胶的制备、表征及抗癌活性. 高等学校化学学报, 2010, 31(5): 964.

ZHANG Wen-Bo*, LIU Chang-Zhong, GAO Lin. Modified Citrus Pectin: Preparation, Characterization and Anti-cancer Activities. Chem. J. Chinese Universities, 2010, 31(5): 964.

参考文献

[1]Platt D., Raz A.. J. Natl. Cancer Inst.[J], 1992, 84(6): 438—442
[2]Nangia-Makker P., Hogan V., Honjo Y., et al.. J. Natl. Cancer Inst.[J], 2002, 94(24): 1854—1862
[3]Sathisha U. V., Jayaram S., Harish Nayaka M. A., et al.. Glycoconj. J.[J], 2007, 24(8): 497—507
[4]Guess B. W., Scholz M. C., Strum S. B., et al.. Prostate Cancer Prostatic. Dis.[J], 2003, 6(4): 301—304
[5]ZHANG Wei-Jie(张惟杰). Biochemistry Research Technology of Glycoconjugate, 2nd Ed.(糖复合物生化研究技术, 第二版)[M] Hangzhou: Zhejiang University Press, 1999: 11—12, 80—81, 140—141
[6]GAO Lin(高林), SHI Xiu-Fang(施秀芳), ZHANG Wen-Bo(张文博). Chem. Ind. Eng.(化学工业与工程)[J], 2005, 22(6):487—489
[7]LIU Yan-Mei(刘岩梅). Food Science(食品科学)[J], 1989, 10(8): 43—45
[8]Whistler R. L., Hickson J. L.. J. Am. Chem. Soc.[J], 1954, 76(6): 1671—1673
[9]Karkhanis Y. D., Zeltner J. Y., Jackson J. J., et al.. Anal. Biochem.[J], 1978, 85(2): 595—601
[10]ZHANG Wen-Bo(张文博), GAO Lin(高林), SHI Xiu-Fang(施秀芳), et al.. Chin. J. Chromatogr.(色谱)[J], 2007, 25(5): 711—714
[11]WANG Ying(王莹), YU Guang-Li(于广利), ZHAO Xia(赵峡), et al.. Chem. J. Chinese Universities(高等学校化学学报)[J], 2005, 26(1): 179—183
[12]Taylor R. L., Conrad H. E.. Biochemistry[J], 1972, 11(8): 1383—1388
[13]FANG Ji-Nian(方积年). Foreign Medical Sciences, Section of Pharmacy(国外医学, 药学分册)[J], 1986, 13(4): 222—226
[14]Pellerin P., Doco T., Vidal S., et al.. Prog. Biotechnol.[J], 1996, 14: 67—78
[15]Jansson P. E., Kenne L., Widmalm G.. Carbohydr. Res.[J], 1989, 188: 169—191
[16]Hayashi A., Gillen A. C., Lott J. R.. Altern. Med. Rev.[J], 2000, 5(6): 546—552
[17]Pienta K. J., Naik H., Akhtar A., et al.. J. Natl. Cancer Inst.[J], 1995, 87(5): 348—353
[18]Jackson C. L., Dreaden T. M., Theobald L. K., et al.. Glycobiology[J], 2007, 17(8): 805—819
[19]Gunning A. P., Bongaerts R. J., Morris V. J.. FASEB J.[J], 2009, 23(2): 415—424
[20]ZHANG Wen-Bo(张文博). Chin. Pharm. J.(中国药学杂志)[J], 2009, 44(3): 165—169
[21]Guo C. H., Koo C. Y., Bay B. H., et al.. Int. J. Oncol.[J], 2007, 31(6): 1415—1423
[22]Glinsky V. V., Raz A.. Carbohydr Res.[J], 2009, 344(14): 1788—1791
[23]Srikanta B. M., Sathisha U. V., Dharmesh S. M.. Biochimie[J], 2009, 92(2): 194—203
[24]Johnson K. D., Glinskii O. V., Mossine V. V., et al.. Neoplasia[J], 2007, 9(8): 662—670
[25]Sathisha U. V., Jayaram S., Harish Nayaka M. A., et al.. Glycoconj. J.[J], 2007, 24(8): 497—507